Venkatesan, Shalini
Fan, Liang
Tang, Hua
Konduru, Nagarjun V.
Shetty, Sreerama
Funding for this research was provided by:
National Institutes of Health (HL151397)
U.S. Department of Defense (W81XWH-20-1-0142)
Flight Attendants Medical Research Institute (CIA award 150063)
Article History
Received: 29 November 2021
Accepted: 13 June 2022
First Online: 30 June 2022
Competing interests
: SS has patents issued for the use of the caveolin-1 spanning domain and its fragments for the treatment of pulmonary fibrosis. SS is a consultant and investor of Lung Therapeutics, Inc, a University of Texas start-up biotechnology firm that is commercializing CSP7 for the treatment of IPF. All others have declared no competing interests.